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The staging system for non–small cell lung cancer (NSCLC) providesa framework for the assessment of prognosis and the assignment oftherapy for all patients with a new diagnosis of lung cancer, esti-mated to be 169,500 in the United States in 2001.1 The most recentrevision of the lung cancer staging system, which considers the sizeand location of the primary tumor (T), the involvement of regional
lymph nodes (N), and the presence of distant metastases (M), is based on the analy-
sis of a collected database representing all clinical, surgical-pathologic, and follow-
up information for 5319 patients treated for primary lung cancer.2 Similar results
have been reported for a population of 6670 patients treated in Japan.3
The power of these large databases in predicting prognosis is self-evident.
Nevertheless, the inherent inaccuracy of the staging process should be brought to
attention. According to the TNM system, the predicted 5-year survival after com-
plete resection for T1 N0 M0 NSCLC (stage IA) is only 67%.1 Therefore 33% of
patients with putative stage IA NSCLC have incorrectly staged disease and will die
of it, predominantly from the development of metastatic disease not detected at the
time of diagnosis and initial therapy.
Molecular biologic staging is the assessment of tumor markers associated with
various oncogenic mechanisms to improve the risk stratification provided by con-
ventional TNM staging. Biologic staging may target oncogenes, oncogenic protein
products, growth factors, or receptors. The biologic techniques used include anti-
body-directed assessment of markers (immunohistochemical assay) and direct
genetic sequencing with single-strand conformational polymorphism or reverse
transcriptase–polymerase chain reaction. Molecular biologic staging may be
applied to the primary tumor, lymph nodes, bone marrow, or serum and used to
establish the diagnosis of malignancy at earlier stage, to assess prognosis, to detect
occult metastases, and to predict chemotherapy resistance.
The purpose of the assessment of prognostic markers in the primary tumor is to
discriminate patients, or groups of patients, with early-stage disease whose risk of
recurrence is sufficiently high to justify adjuvant therapy. The use of a panel of mark-
ers may improve the effectiveness of this approach, because expression of individual
oncogenic markers is low in NSCLC: p53 and epidermal growth factor receptor are
expressed in approximately 43% and 52% of tumors, respectively.4 Studies that eval-
uate molecular prognostic variables must be limited to early-stage disease; the inclu-
sion of patients with advanced-stage disease dilutes the potential prognostic value of
the markers, because that subgroup of patients would have a dismal prognosis
regardless of marker status.4,5 In a study of patients with stage I disease, molecular
substaging discriminated groups of patients with 5-year survivals ranging from 37%
(5 negative prognostic markers) to 80% (1 negative prognostic marker).
Molecular markers that are assessed to detect the presence of occult metastases in
lymph nodes, bone marrow, or serum should have a high prevalence, and the tech-
niques to measure these marker must have high sensitivity and specificity. The intrin-
sic prognostic value of the markers as related to the primary tumor is irrelevant; the
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diagnostic or prognostic value of these markers is determined
by their presence in distant sites, suggesting occult metasta-
tic disease. Currently the most effective markers to detect
occult metastases are epithelial markers, such as cytokeratins,
which are present in 70% to 80% of tumors but are not nor-
mally present in lymph nodes, bone marrow, or serum.6-8
The ability of molecular biologic markers to predict
results of chemotherapy would enable the clinician to
design therapy for the individual tumor. In addition, identi-
fying and understanding the mechanisms of treatment resis-
tance offers another pathway to intervene, by blocking or
reversing the mechanism of resistance. Furthermore, the
understanding of the molecular mechanism of receptor
activity and DNA repair enables the study of pharmacologic
targeting with chemotherapy or biologic agents, such as
epidermal growth factor receptor antibodies or tyrosine
kinase inhibitors.9
The study by Ahrendt and colleagues10 in this issue of
the Journal uses molecular techniques to detect occult
micrometastases in the lymph nodes of patients with com-
pletely resected stage I NSCLC and attempts to correlate
the presence of micrometastatic disease with prognosis.10
Contrary to most similar studies, this report did not find that
the presence of occult lymph node metastases altered sur-
vival. Ahrendt and colleagues chose two gene markers, K-
ras and TP53, which have prevalences of 44% and 52%,
respectively; the ability to detect micrometastatic disease
with markers present in only half of the patients limits the
utility of this technique. The ideal marker for detecting
occult metastatic disease would be present in nearly all
tumors and would be undetectable in the lymph nodes, bone
marrow, and serum of control subjects.
Molecular biologic substaging of patients with stage I
NSCLC may have the potential to alter therapy, in addition
to improving risk stratification. In a recent study the prog-
nostic value of the molecular markers was more powerful
than that of lymph node involvement.11 The effectiveness of
chemotherapy for patients with stage IB NSCLC is being
evaluated in an ongoing Cancer and Leukemia Group B
(CALGB) protocol, CALGB 9633. In this study, patients
with completely resected stage IB NSCLC are randomly
assigned to receive postoperative chemotherapy (carbo-
platin and paclitaxel) or observation; all patients in the
study will have tumors analyzed for a panel of molecular
markers to determine the prognostic significance of the
markers with respect to chemotherapy.
The ultimate power of molecular biologic substaging
depends on the ability to alter therapy and improve out-
come, which has not yet been demonstrated. With current
technology, however, it would be possible to perform a
biopsy on a patient with clinical stage I NSCLC and deter-
mine the relative prognosis on the basis of the molecular
substaging. Patients with strong negative prognostic mark-
ers and patients with occult metastases in the bone marrow
or serum might be treated with induction biologic therapy
or chemotherapy; furthermore, the choice of agents would
be determined by the biologic characteristics of the tumor.
Other applications of biologic staging include sentinel
lymph node assessment, which would allow pathologists to
focus more intensely on a limited amount of tissue to detect
occult metastatic disease.12 This strategy will become even
more accurate with the development of real-time reverse
transcriptase–polymerase chain reaction, enabling the intra-
operative analysis of genetic mutations. In the near future it
is possible that patients with NSCLC will have their disease
staged and treated according to a TNMB staging system:
tumor, nodes, metastases, and biology.
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